One Day, Two Peptide Headlines: What July 23 Means for Reta and the Wolverine Blend, a GMR Peptides Analysis
July 23, 2026 was a busy day for anyone following peptides. That day, Eli Lilly announced that retatrutide had succeeded in two more Phase 3 obesity trials, TRIUMPH-2 and TRIUMPH-3, and said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. The same day, the FDA’s Pharmacy…